ABVC BioPharma Reports $1.27 Million Q3 Licensing Revenue as CNS Pipeline Advances Toward Phase III
Key Insights
ABVC BioPharma (search) generated $1.27 million in Q3 2025 licensing revenue from partnerships with AiBtl BioPharma (search), ForSeeCon Eye Corporation (search), and OncoX BioPharma (search).
The company's lead CNS candidate ABV-1504 for major depressive disorder (search) has completed Phase II trials and is preparing for global Phase III development.
ABVC's assets grew 103% year-over-year to $16.2 million in Q2 2025, with shareholder equity rising 18.7%.
ABVC BioPharma (search), Inc. (NASDAQ: ABVC) reported $1.27 million in licensing revenue for Q3 2025 while advancing its central nervous system pipeline toward Phase III trials. The clinical-stage biopharmaceutical company was recently highlighted by Insider Monkey as one of the "Best Biotech Penny Stocks" to invest in, recognizing its financial growth and advancing therapeutic pipeline.
Strong Financial Performance Drives Growth
The company demonstrated robust financial momentum with Q2 2025 assets growing 103% year-over-year to $16.2 million, while shareholder equity increased 18.7%. The Q3 licensing revenue of $1,275,950 was contributed by strategic partnerships with AiBtl BioPharma (search), ForSeeCon Eye Corporation (search), and OncoX BioPharma (search).
"We acknowledge that ABVC is currently categorized as a penny stock, but we believe this is simply a stage in our growth journey," said Dr. Uttam Patil, ABVC's Chief Executive Officer. "Recognition by a financial media outlet, solid Q3 licensing revenue, and well-defined pipeline progress is helping to lay the foundation for potential long-term revaluation."
CNS Pipeline Shows Clinical Promise
ABVC's central nervous system portfolio centers on PDC-1421, a compound derived from Radix Polygala (search) targeting psychiatric disorders (search) with potentially fewer side effects than current treatments. The program includes two distinct formulations: ABV-1504 for major depressive disorder (search) and ABV-1505 for attention deficit hyperactivity disorder (search). The Phase IIb Clinical Study Report has been submitted to the FDA.
ABV-1504 represents a potential safer alternative to Prozac for treating major depressive disorder (search). The candidate has completed Phase II development and is now preparing for global Phase III trials, marking a significant milestone in the company's CNS strategy.
Oncology Programs Advance Through Phase II
The company's oncology pipeline includes two active Phase II programs. BLI-1401 is being evaluated for metastatic pancreatic cancer (search), while BLI-1301 targets myelodysplastic syndromes (search). Both programs continue to progress through mid-stage clinical development.
Research Network and Development Strategy
ABVC BioPharma (search) operates with an active pipeline of six drugs and one medical device, ABV-1701 (search)/Vitargus (search)®, under development. The company leverages in-licensed technology from world-renowned research institutions including Stanford University, University of California at San Francisco (search), and Cedars-Sinai Medical Center to conduct proof-of-concept trials through Phase II clinical development.
For its Vitargus (search)® medical device program, ABVC intends to conduct pivotal Phase III clinical trials through global partnerships, representing a different strategic approach from its drug development programs.